- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 211/60
Total number of patents in this class: 567
10-year publication summary
|
72
|
47
|
42
|
51
|
58
|
41
|
42
|
32
|
35
|
11
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| ChemoCentryx, Inc. | 400 |
29 |
| Meiji Seika Pharma Co., Ltd. | 244 |
16 |
| Novartis AG | 11238 |
14 |
| Corsair Pharma, Inc. | 35 |
12 |
| API Corporation | 211 |
11 |
| Life Technologies Corporation | 3068 |
10 |
| Biogen MA Inc. | 926 |
10 |
| Xinfa Pharmaceutical Co., Ltd. | 28 |
10 |
| Bristol-myers Squibb Company | 5080 |
8 |
| Kaneka Corporation | 4445 |
8 |
| Omeros Corporation | 286 |
8 |
| Helsinn Healthcare SA | 255 |
7 |
| Takeda Pharmaceutical Company Limited | 2961 |
6 |
| Global Blood Therapeutics, Inc. | 180 |
6 |
| F. Hoffmann-La Roche AG | 7958 |
5 |
| The Regents of the University of California | 18943 |
5 |
| West China Hospital, Sichuan University | 170 |
5 |
| AstraZeneca AB | 3042 |
4 |
| Janssen Pharmaceutica N.V. | 3839 |
4 |
| Glaxosmithkline Intellectual Property Development Limited | 723 |
4 |
| Other owners | 385 |